CSL agrees Alentis partnership as CSL stock trades at EUR 117.33
Published on 10/18/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPartnership and trading update
- CSL and Alentis announced a rare-disease partnership on October 5, 2026, including a US$355 million initial payment and up to US$1.2 billion in milestones.
- CSL stock trades in weekend trading at EUR 117.33 at 5:02 p.m. CEST at Lang & Schwarz on October 18, 2026.
- The next Xetra session is scheduled for October 19, 2026.
CSL and Alentis announced a global partnership on October 5, 2026, to develop and commercialize lixudebart for rare kidney and liver diseases, according to CSL. The announcement includes a US$355 million initial payment for Alentis and up to US$1.2 billion in commercial milestones, with global profits shared.
Weekend trading
CSL stock trades in weekend trading at Lang & Schwarz at EUR 117.33 at 5:02 p.m. CEST on October 18, 2026. The bid is EUR 116.86 and the ask is EUR 117.80. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of CSL stock.
Market context: Market report S&P/ASX 200.
Chronology of the week
On October 5, 2026, CSL and Alentis announced the rare-disease partnership covering lixudebart, a potential treatment for kidney and liver diseases. The arrangement provides for the initial payment and commercial milestones described by CSL in its release.
Dates ahead
The next Xetra session is scheduled for October 19, 2026. CSL's recent partnership announcement remains the latest dated company development supported by the cited CSL release.
